203 related articles for article (PubMed ID: 33761014)
1. Dual Enkephalinase Inhibitors and Their Role in Chronic Pain Management.
Southerland WA; Gillis J; Kuppalli S; Fonseca A; Mendelson A; Horine SV; Bansal N; Gulati A
Curr Pain Headache Rep; 2021 Mar; 25(5):29. PubMed ID: 33761014
[TBL] [Abstract][Full Text] [Related]
2. Indirect-acting strategy of opioid action instead of direct receptor activation: dual-acting enkephalinase inhibitors (DENKIs).
Raffa RB; Pergolizzi JV; Taylor R; Ossipov MH;
J Clin Pharm Ther; 2018 Aug; 43(4):443-449. PubMed ID: 29722031
[TBL] [Abstract][Full Text] [Related]
3. Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain.
González-Rodríguez S; Poras H; Menéndez L; Lastra A; Ouimet T; Fournié-Zaluski MC; Roques BP; Baamonde A
Scand J Pain; 2017 Jan; 14():25-38. PubMed ID: 28850427
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of enkephalin catabolism by dual enkephalinase inhibitor: A novel possible therapeutic approach for opioid use disorders.
Alvarez-Perez B; Poras H; Maldonado R
Br J Pharmacol; 2023 Apr; 180(7):879-893. PubMed ID: 34378790
[TBL] [Abstract][Full Text] [Related]
5. Contribution of Delta-Opioid Receptors to Pathophysiological Events Explored by Endogenous Enkephalins.
Roques BP
Handb Exp Pharmacol; 2018; 247():53-70. PubMed ID: 27417433
[TBL] [Abstract][Full Text] [Related]
6. New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment.
Poras H; Bonnard E; Dangé E; Fournié-Zaluski MC; Roques BP
J Med Chem; 2014 Jul; 57(13):5748-63. PubMed ID: 24927250
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction.
Roques BP; Noble F
NIDA Res Monogr; 1995; 147():104-45. PubMed ID: 8742783
[No Abstract] [Full Text] [Related]
8. Modulation of disulfide dual ENKephalinase inhibitors (DENKIs) activity by a transient N-protection for pain alleviation by oral route.
Poras H; Bonnard E; Fournié-Zaluski MC; Roques BP
Eur J Med Chem; 2015 Sep; 102():58-67. PubMed ID: 26241877
[TBL] [Abstract][Full Text] [Related]
9. Use of preproenkephalin knockout mice and selective inhibitors of enkephalinases to investigate the role of enkephalins in various behaviours.
Noble F; Benturquia N; Bilkei-Gorzo A; Zimmer A; Roques BP
Psychopharmacology (Berl); 2008 Feb; 196(2):327-35. PubMed ID: 17906961
[TBL] [Abstract][Full Text] [Related]
10. Aminophosphinic inhibitors as transition state analogues of enkephalin-degrading enzymes: a class of central analgesics.
Chen H; Noble F; Coric P; Fournie-Zaluski MC; Roques BP
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):12028-33. PubMed ID: 9751784
[TBL] [Abstract][Full Text] [Related]
11. Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities.
Chen H; Noble F; Mothé A; Meudal H; Coric P; Danascimento S; Roques BP; George P; Fournié-Zaluski MC
J Med Chem; 2000 Apr; 43(7):1398-408. PubMed ID: 10753476
[TBL] [Abstract][Full Text] [Related]
12. [Anti-arrhythmia effects of enkephalinase inhibitors].
Lishmanov IuB; Maslov LN; Uskina EV
Eksp Klin Farmakol; 2001; 64(5):28-30. PubMed ID: 11764494
[TBL] [Abstract][Full Text] [Related]
13. In vivo occupation of mouse brain opioid receptors by endogenous enkephalins: blockade of enkephalin degrading enzymes by RB 101 inhibits [3H]diprenorphine binding.
Ruiz-Gayo M; Baamonde A; Turcaud S; Fournie-Zaluski MC; Roques BP
Brain Res; 1992 Feb; 571(2):306-12. PubMed ID: 1319268
[TBL] [Abstract][Full Text] [Related]
14. Role of delta opioid receptors in the effects of inhibitors of enkephalin-degrading peptidases on the horizontal and vertical components of locomotion in mice.
Michael-Titus A; Dourmap N; Costentin J; Schwartz JC
Neuropeptides; 1990 Feb; 15(2):89-100. PubMed ID: 1981928
[TBL] [Abstract][Full Text] [Related]
15. [Characteristics of effects of mu-, delta-, and kappa-opioid agonists and enkephalinase inhibitor RB101 in rats of two inbred strains].
Sudakov SK; Liupina IuV; Medvedeva OF; Tiurina IV; Maldonado R
Biull Eksp Biol Med; 1998 May; 125(5):551-4. PubMed ID: 9644557
[No Abstract] [Full Text] [Related]
16. Long-lasting oral analgesic effects of N-protected aminophosphinic dual ENKephalinase inhibitors (DENKIs) in peripherally controlled pain.
Bonnard E; Poras H; Nadal X; Maldonado R; Fournié-Zaluski MC; Roques BP
Pharmacol Res Perspect; 2015 Mar; 3(2):e00116. PubMed ID: 25692029
[TBL] [Abstract][Full Text] [Related]
17. Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders.
Szymaszkiewicz A; Storr M; Fichna J; Zielinska M
Neurogastroenterol Motil; 2019 Apr; 31(4):e13526. PubMed ID: 30549162
[TBL] [Abstract][Full Text] [Related]
18. Facilitation of enkephalins catabolism inhibitor-induced antinociception by drugs classically used in pain management.
Nieto MM; Wilson J; Walker J; Benavides J; Fournié-Zaluski MC; Roques BP; Noble F
Neuropharmacology; 2001 Sep; 41(4):496-506. PubMed ID: 11543770
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin.
Menéndez L; Hidalgo A; Meana A; Poras H; Fournié-Zaluski MC; Roques BP; Baamonde A
Eur J Pharmacol; 2008 Oct; 596(1-3):50-5. PubMed ID: 18692494
[TBL] [Abstract][Full Text] [Related]
20. Neprilysin Controls the Synaptic Activity of Neuropeptides in the Intercalated Cells of the Amygdala.
Gregoriou GC; Patel SD; Winters BL; Bagley EE
Mol Pharmacol; 2020 Oct; 98(4):454-461. PubMed ID: 32606204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
